Overview

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medicago
Collaborator:
Mitsubishi Tanabe Pharma Corporation